Telix Pharmaceuticals (NASDAQ:TLX) Sees Large Volume Increase - Here's What Happened

Key Points

• Telix Pharmaceuticals experienced a significant increase in trading volume, with 167,084 shares traded on Wednesday, a 114% rise from the previous session.
• Analysts have mixed ratings for Telix Pharmaceuticals, with one “Strong Buy,” five “Buy,” one “Hold,” and one “Sell” rating, while the average consensus target price is set at $21.00.
• The stock price rose by 8.1%, closing at $11.23 after previously settling at $10.04, but remains below its 200-day moving average of $14.22.

Telix Pharmaceuticals Limited (NASDAQ:TLX - Get Free Report) saw an uptick in trading volume on Wednesday . 167,084 shares traded hands during mid-day trading, an increase of 114% from the previous session's volume of 78,063 shares.The stock last traded at $11.23 and had previously closed at $10.04.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. Weiss Ratings reaffirmed a "sell (d)" rating on shares of Telix Pharmaceuticals in a research note on Wednesday, October 8th. HC Wainwright reduced their target price on Telix Pharmaceuticals from $23.00 to $20.00 and set a "buy" rating for the company in a report on Wednesday, September 10th. UBS Group reduced their price objective on Telix Pharmaceuticals from $23.00 to $20.00 and set a "buy" rating for the company in a research note on Tuesday, September 23rd. Citigroup started coverage on Telix Pharmaceuticals in a research report on Thursday, September 18th. They set a "buy" rating and a $22.00 target price on the stock. Finally, William Blair restated an "outperform" rating on shares of Telix Pharmaceuticals in a report on Wednesday, July 9th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $21.00.

Telix Pharmaceuticals Stock Up 8.1%

The stock has a 50 day simple moving average of $10.35 and a 200 day simple moving average of $14.22.

Institutional Investors Weigh In On Telix Pharmaceuticals

A number of large investors have recently bought and sold shares of the business. Pier Capital LLC bought a new stake in shares of Telix Pharmaceuticals in the second quarter valued at about $3,037,000. Russell Investments Group Ltd. acquired a new stake in shares of Telix Pharmaceuticals in the second quarter valued at approximately $975,000. Jane Street Group LLC acquired a new stake in Telix Pharmaceuticals during the 2nd quarter worth $564,000. ABC Arbitrage SA bought a new position in shares of Telix Pharmaceuticals during the first quarter worth $451,000. Finally, Vanguard Personalized Indexing Management LLC bought a new position in shares of Telix Pharmaceuticals during the second quarter worth $297,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.